Phase II Study Using Thalidomide for the Treatment of ALS

• Status: Completed
• Trial end date: 2007-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The use of Thalidomide in patients with ALS who have disease progression.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Dartmouth-Hitchcock Medical Center
• Collaborator: Celgene Corporation
• Treatments: Thalidomide

Criteria

Inclusion Criteria:

• Clinically proven ALS

• Disease duration less than or equal to 5 years

• ALSFRS-R score equal to or greater then 30

Exclusion Criteria:

• Patients with known deep venous thrombosis or hyper coagulable state will be excluded

• Patients with FVC less than 80%